Hana Biosciences to Present at the Cowen & Co. 26th Annual Health Care Conference
28 Febbraio 2006 - 2:30PM
Business Wire
Hana Biosciences (AMEX:HBX) announced today that Mark Ahn, PhD,
President & Chief Executive Officer, will present a company
update at the Cowen & Co. 26th Annual Health Care Conference on
Thursday, March 9th, at 8:50 AM ET in the Harvard Meeting Room on
the 3rd floor at the Boston Marriott Copley Place. A live audio
webcast of the presentation can be accessed on the investor
relations page of the company's website, www.hanabiosciences.com.
An audio replay of the presentation will also be available for 90
days after the conference. About Hana Biosciences Hana Biosciences,
Inc. (AMEX:HBX) is a South San Francisco, CA-based
biopharmaceutical company that acquires, develops, and
commercializes innovative products to advance cancer care. The
company is committed to creating value by building a world-class
team, accelerating the development of lead product candidates,
expanding its pipeline by being the alliance partner of choice, and
nurturing a unique company culture. Additional information on Hana
Biosciences can be found at www.hanabiosciences.com. This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements involve risks and uncertainties that could cause Hana's
actual results to differ materially from the anticipated results
and expectations expressed in these forward-looking statements.
These statements are based on current expectations, forecasts and
assumptions that are subject to risks and uncertainties, which
could cause actual outcomes and results to differ materially from
these statements. Among other things, there can be no assurances
that any of Hana's development efforts relating to its product
candidates will be successful. Other risks that may affect
forward-looking information contained in this press release include
the possibility of being unable to obtain regulatory approval of
Hana's product candidates, the risk that the results of clinical
trials may not support Hana's claims, Hana's reliance on
third-party researchers to develop its product candidates, and its
lack of experience in developing pharmaceutical products.
Additional risks are described in the company's Annual Report on
Form 10-KSB for the year ended Dec. 31, 2004. Hana assumes no
obligation to update these statements, except as required by law.
Grafico Azioni Hana Biosciences (AMEX:HBX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Hana Biosciences (AMEX:HBX)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Hana Biosciences (Borsa Americana (AMEX)): 0 articoli recenti
Più Hana Biosciences, Inc. Articoli Notizie